Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies

Oncologist

Volumn 6, Issue SUPPL. 5, 2001, Pages 24-31

  List, A F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Angiogenesis; Hematologic malignancy; Receptor tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

INTEGRIN; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE LEUKEMIA; ANGIOGENESIS; BLOOD DISEASE; CHRONIC LEUKEMIA; CONFERENCE PAPER; DIABETIC RETINOPATHY; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; OVULATION; PARACRINE SIGNALING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WOUND HEALING;

EID: 0035167615     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_5-24     Document Type: Conference Paper

References (60)

1. The hallmarks of cancer
2. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
3. Molecular angiogenesis
4. Angiogenesis: Models and modulators
5. Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo
6. Evidence of increased angiogenesis in patients with acute myeloid leukemia
7. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
8. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
9. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
10. Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features
11. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer
12. Vascular endothelial growth factor: Molecular and biological aspects
13. Interleukin 6 induces the expression of vascular endothelial growth factor
14. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
15. Vascular endothelial growth factor (VEGF) and its receptors
16. Role of αv integrins during angiogenesis
17. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
18. A novel vascular endothelial growth factor encoded by Orf virus, VEGF- E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
19. VEGF receptor signaling in tumor angiogenesis
20. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression
21. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
22. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction
23. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
24. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
25. (-1-) embryonic stem cells and embryos
26. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
27. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
28. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src
29. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells
30. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
31. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins
32. Regulation of angiogenesis via vascular endothelial growth factor receptors
33. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
34. Haemopoiesis in long-term bone marrow cultures. A review
35. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2
36. Repopulation of liver endothelium by bone-marrow-derived cells
37. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells
38. (+) cells identifies a population of functional endothelial precursors
39. Vascular endothelial growth factor is a secreted angiogenic mitogen
40. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
41. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
42. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
43. WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis
44. Intratumoral microvascular density in malignant lymphomas of B-cell origin
45. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia
46. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
47. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
48. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
49. Mechanisms of myeloma cell growth control
50. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
51. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
52. Prognostic value of bone marrow angiogenesis in multiple myeloma
53. Angiogenesis in myelodysplastic syndromes
54. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
55. Novel therapeutic agents for the treatment of myelodysplastic syndromes
56. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methyli-denyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
57. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
58. SU6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties
59. SU5416 and SU6668 inhibit biological functions of c-kit in a myeloid leukemia cell line and in AML blasts
60. VEGFR-1 (Flt-1) and VEGFR-2 (KDR) stimulate the proliferation of AML cells via the P13-kinase and AKT/protein kinase-B (PKB) signal pathway